Regenesis Biomedical has announced that the US Food and Drud Administration (FDA) has approved the removal of the contraindication for use of the company's Provant therapy system in patients with metallic implants in the area of treatment.
The decision was made after the FDA reviewed additional data and research demonstrating that the use of Provant's pulsed electromagnetic therapy (PEMT) did not put such patients at risk.
Regenesis Biomedical president and CEO Scott S Brooks noted the positive effects of using our non-thermal PEMT Therapy to treat patients with persistent post operative pain have been reported by both doctors and patients.
"The FDA's decision to approve the removal of this contraindication for the Provant System allows many more patients to benefit from Provant Therapy.
"The clinical literature reports a significant unmet need for effective pain therapies in patients undergoing orthopedic surgery. A recent case series shows Provant Therapy may be beneficial for treating Failed Back Surgery Syndrome (FBSS) patients as a means to avoid more invasive and expensive therapies.
"This decision by the FDA expands the number of patients who might benefit from Provant Therapy. We are now actively engaging orthopedic, podiatric, primary care, and rehabilitation clinicians to educate them on the benefits of Provant Therapy for resolution of postoperative pain. Provant is a non-narcotic, non-invasive and safe option for patients in need," Brooks added.
